

FACT SHEET As of 3/31/25

PHARMACEUTICALS ULTRASECTOR PROFUND

Fund objective

Pharmaceuticals UltraSector ProFund seeks daily investment results, before fees and expenses, that correspond to one and one-half times (1.5x) the daily performance of the S&P Pharmaceuticals Select Industry Index. The Fund does not seek to achieve its stated investment objective over a period of time greater than a single day.

Fund details

Inception Date	06/28/2000
Investor Class Symbol	PHPIX
Service Class Symbol	PHPSX
Investor Class Cusip	743185423
Service Class Cusip	743185415
Investor Class Gross Expense Ratio	2.50%
Service Class Gross Expense Ratio	3.50%
Investor Class Net Expense Ratio ¹	1.78%
Service Class Net Expense Ratio ¹	2.78%
Limit on Exchange	None

Uses for magnified exposure

Common uses for magnified exposure include:

- Seeking magnified gains (will also magnify losses)
- Getting a target level of exposure for less cash
- Overweighting a market segment without additional cash

Fund performance and index history²


The Pharmaceuticals UltraSector ProFund seeks daily investment results, before fees and expenses, that are 1.5x the return of the S&P Pharmaceuticals Select Industry Index (the "Index") for a single day, not for any other period.

	1Q 2025	Year to Date	1-Year	5-Year	10-Year	Fund Inception
Investor Class NAV Total Return	2.03%	2.03%	-1.29%	7.86%	1.69%	2.20%
Service Class NAV Total Return	1.76%	1.76%	-2.20%	6.82%	0.68%	1.21%
S&P Pharmaceuticals Select Industry	2.33%	2.33%	2.95%	5.15%	-1.83%	6.27%
Dow Jones U.S. Select Pharmaceuticals	8.02%	8.02%	5.98%	11.55%	3.94%	—

Periods greater than one year are annualized.

On 8/28/18 the benchmark for this fund changed from tracking the Dow Jones U.S. Sector indexes to Dow Jones U.S. Select Sector Indexes (inception 4/28/06)

Daily return during 1Q 2025




Past performance does not guarantee future results. The performance data quoted represents past performance and current returns may be lower or higher. The investment return and principal value of an investment will fluctuate so that an investor's shares, when redeemed, may be worth more or less than the original cost. Performance data current to the most recent month-end is available at Profunds.com or by calling 1-888-776-3637.

For standardized returns year-to-date, and as of the most recent calendar quarter-end, and annualized month-end, see performance. Returns include the reinvestment of dividends and capital gains.

¹Contractual waiver effective until November 30, 2025. Without such a waiver of fees, the total returns would have been lower.

²All data, unless otherwise noted, is as of 12/31/2024, and for Investor Class Shares only. Holdings and other data are subject to change.

<div> Index description² </div> <div> <p>The Index represents the pharmaceuticals segment of the S&P Total Market Index ("S&P TMI"). The S&P TMI is designed to track the broad U.S. equity market. The pharmaceuticals segment of the S&P TMI comprises the following Global Industry Classification Standard (GICS®) sub-industry: pharmaceuticals.</p> </div>	<div> <div> Top index companies² Weights </div> <table> <tr><td>Corcept Therapeutics Inc.</td><td>7.45%</td></tr> <tr><td>Tarsus Pharmaceuticals Inc.</td><td>3.72%</td></tr> <tr><td>Perrigo Co. plc</td><td>3.66%</td></tr> <tr><td>Bristol-Myers Squibb Co.</td><td>3.66%</td></tr> <tr><td>Zoetis Inc.</td><td>3.65%</td></tr> <tr><td>Johnson & Johnson</td><td>3.65%</td></tr> <tr><td>Elanco Animal Health Inc.</td><td>3.62%</td></tr> <tr><td>Intra-Cellular Therapies Inc.</td><td>3.60%</td></tr> <tr><td>Eli Lilly & Co.</td><td>3.60%</td></tr> <tr><td>Organon & Co.</td><td>3.56%</td></tr> </table> </div>	Corcept Therapeutics Inc.	7.45%	Tarsus Pharmaceuticals Inc.	3.72%	Perrigo Co. plc	3.66%	Bristol-Myers Squibb Co.	3.66%	Zoetis Inc.	3.65%	Johnson & Johnson	3.65%	Elanco Animal Health Inc.	3.62%	Intra-Cellular Therapies Inc.	3.60%	Eli Lilly & Co.	3.60%	Organon & Co.	3.56%
Corcept Therapeutics Inc.	7.45%																				
Tarsus Pharmaceuticals Inc.	3.72%																				
Perrigo Co. plc	3.66%																				
Bristol-Myers Squibb Co.	3.66%																				
Zoetis Inc.	3.65%																				
Johnson & Johnson	3.65%																				
Elanco Animal Health Inc.	3.62%																				
Intra-Cellular Therapies Inc.	3.60%																				
Eli Lilly & Co.	3.60%																				
Organon & Co.	3.56%																				
<div> Index Characteristics² </div> <div> <table> <tr><td>Number of Companies</td><td>43</td></tr> <tr><td>Price/Earnings Ratio</td><td>21.67</td></tr> <tr><td>Price/Book Ratio</td><td>2.85</td></tr> <tr><td>Dividend Yield</td><td>1.51%</td></tr> <tr><td>Average Market Cap</td><td>\$43.28 billion</td></tr> </table> </div>	Number of Companies	43	Price/Earnings Ratio	21.67	Price/Book Ratio	2.85	Dividend Yield	1.51%	Average Market Cap	\$43.28 billion	<div> <div> Index sectors² Weights³ </div> <table> <tr><td>Pharmaceuticals</td><td>100.00%</td></tr> </table>  </div>	Pharmaceuticals	100.00%								
Number of Companies	43																				
Price/Earnings Ratio	21.67																				
Price/Book Ratio	2.85																				
Dividend Yield	1.51%																				
Average Market Cap	\$43.28 billion																				
Pharmaceuticals	100.00%																				
<div> For more information, visit ProFunds.com or ask your financial advisor or broker. </div>																					

Narrowly focused investments typically exhibit higher volatility.

Many ProFunds seek daily investment results that correspond, before fees and expenses, to a multiple (e.g., 2x, -2x) of the daily performance of its underlying benchmark (the "Daily Target"). While these Funds have a daily investment objective, you may hold Fund shares for longer than one day if you believe it is consistent with your goals and risk tolerance. For any holding period other than a day, your return may be higher or lower than the Daily Target. These differences may be significant. Smaller index gains/losses and higher index volatility contribute to returns worse than the Daily Target. Larger index gains/losses and lower index volatility contribute to returns better than the Daily Target. The more extreme these factors are, the more they occur together, and the longer your holding period while these factors apply, the more your return will tend to deviate. Investors should consider periodically monitoring their geared fund investments in light of their goals and risk tolerance.

ProFunds are not suitable for all investors because of the sophisticated techniques the funds employ. Investing involves risk, including the possible loss of principal. ProFunds entail certain risks, including risk associated with the use of derivatives (swap agreements, futures contracts and similar instruments), imperfect benchmark correlation, leverage and market price variance, all of which can increase volatility and decrease performance. For more on correlation, leverage and other risks, please read the prospectus. There is no guarantee any ProFund will achieve its investment objective.

All ProFunds are subject to active investor risk. There are no restrictions on the size and frequency of trades and no transaction fees. The frequent exchanges our policies permit can decrease performance, increase expenses and cause investors to incur tax consequences.

Carefully consider the investment objectives, risks, charges and expenses of ProFunds before investing. A prospectus or summary prospectus with this and other information may be obtained at Profunds.com or by calling 1-888-776-3637. Read them carefully before investing.

³Sum of weightings may not equal 100% due to rounding.

ProFunds are distributed by ProFunds Distributors Inc.© 2024